BridgeBio Oncology Therapeutics, Inc Financials
This page shows BridgeBio Oncology Therapeutics, Inc (BBOT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BridgeBio Oncology Therapeutics, Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, BridgeBio Oncology Therapeutics, Inc generates $-0.10 in operating cash flow (-$764K OCF vs $7.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
BridgeBio Oncology Therapeutics, Inc reported $7.6M in net income in fiscal year 2024. This represents an increase of 18327.7% from the prior year.
BridgeBio Oncology Therapeutics, Inc held $30.9M in cash against $0 in long-term debt as of fiscal year 2024.
BridgeBio Oncology Therapeutics, Inc had 28,415 shares outstanding in fiscal year 2024.
BBOT Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $35.1M | N/A | N/A | N/A | $17.9M | N/A | N/A | N/A |
| SG&A Expenses | $14.1M+1159.4% | $1.1M-53.7% | $2.4M | N/A | $1.8M+1065.1% | $152K+128.4% | $67K | N/A |
| Operating Income | -$49.2M-4283.9% | -$1.1M+53.7% | -$2.4M | N/A | -$19.7M-12807.7% | -$152K-128.4% | -$67K | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | $0 | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$44.8M-57.4% | -$28.4M-28.9% | -$22.1M | N/A | -$17.3M+20.6% | -$21.8M-41.3% | -$15.4M | N/A |
| EPS (Diluted) | $-1.03 | N/A | N/A | N/A | $-1562.18 | N/A | N/A | N/A |
BBOT Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $484.8M+145.6% | $197.4M+0.9% | $195.7M+19.1% | $164.3M-14.6% | $192.3M+1.3% | $189.9M+1.3% | $187.5M+56232.9% | $333K |
| Current Assets | $476.0M+54190.8% | $877K-29.3% | $1.2M-99.2% | $158.7M+7672.2% | $2.0M-1.6% | $2.1M-1.6% | $2.1M | N/A |
| Cash & Equivalents | $408.7M+61436.0% | $664K-31.0% | $963K-96.9% | $30.9M+51.2% | $20.4M+1024.8% | $1.8M-1.6% | $1.8M+637.4% | $250K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $38.1M-91.0% | $425.1M+7.4% | $395.7M+15.4% | $342.9M-2.4% | $351.5M+5.5% | $333.3M+5.3% | $316.4M+172.8% | $116.0M |
| Current Liabilities | $35.7M+1258.5% | $2.6M+40.5% | $1.9M-90.4% | $19.6M+15355.0% | $127K+60.1% | $79K+239.2% | $23K-94.1% | $396K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $446.7M+296.2% | -$227.7M-13.8% | -$200.0M-12.0% | -$178.6M-12.2% | -$159.2M-11.0% | -$143.4M-11.3% | -$128.9M-11.4% | -$115.6M |
| Retained Earnings | -$317.8M-4269.4% | -$7.3M-18.2% | -$6.2M+97.2% | -$222.5M-6225.6% | -$3.5M-4.3% | -$3.4M-4.7% | -$3.2M-3537.4% | -$89K |
BBOT Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$70.6M-23528.5% | -$299K+59.3% | -$735K-101.9% | $39.2M+199.7% | -$39.3M-135110.5% | -$29K+95.3% | -$618K | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | -$37.9M-200.0% | $37.9M | $0+100.0% | -$184.0M | N/A |
| Financing Cash Flow | N/A | N/A | N/A | -$19.8M-200.0% | $19.8M | $0-100.0% | $186.5M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BBOT Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.2%+5.2pp | -14.4%-3.1pp | -11.3% | N/A | -9.0%+2.5pp | -11.5%-3.3pp | -8.2% | N/A |
| Current Ratio | 13.33+13.0 | 0.33-0.3 | 0.66-7.4 | 8.10-8.0 | 16.12-10.1 | 26.23-64.2 | 90.42 | N/A |
| Debt-to-Equity | 0.09+2.0 | -1.87+0.1 | -1.98-0.1 | -1.92+0.3 | -2.21+0.1 | -2.32+0.1 | -2.46-1.5 | -1.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$178.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is BridgeBio Oncology Therapeutics, Inc profitable?
Yes, BridgeBio Oncology Therapeutics, Inc (BBOT) reported a net income of $7.6M in fiscal year 2024.
What is BridgeBio Oncology Therapeutics, Inc's operating cash flow?
BridgeBio Oncology Therapeutics, Inc (BBOT) generated -$764K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are BridgeBio Oncology Therapeutics, Inc's total assets?
BridgeBio Oncology Therapeutics, Inc (BBOT) had $164.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does BridgeBio Oncology Therapeutics, Inc have outstanding?
BridgeBio Oncology Therapeutics, Inc (BBOT) had 28,415 shares outstanding as of fiscal year 2024.
What is BridgeBio Oncology Therapeutics, Inc's current ratio?
BridgeBio Oncology Therapeutics, Inc (BBOT) had a current ratio of 8.10 as of fiscal year 2024, which is generally considered healthy.
What is BridgeBio Oncology Therapeutics, Inc's debt-to-equity ratio?
BridgeBio Oncology Therapeutics, Inc (BBOT) had a debt-to-equity ratio of -1.92 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BridgeBio Oncology Therapeutics, Inc's return on assets (ROA)?
BridgeBio Oncology Therapeutics, Inc (BBOT) had a return on assets of 4.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is BridgeBio Oncology Therapeutics, Inc's cash runway?
Based on fiscal year 2024 data, BridgeBio Oncology Therapeutics, Inc (BBOT) had $30.9M in cash against an annual operating cash burn of $764K. This gives an estimated cash runway of approximately 485 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is BridgeBio Oncology Therapeutics, Inc's debt-to-equity ratio negative or unusual?
BridgeBio Oncology Therapeutics, Inc (BBOT) has negative shareholder equity of -$178.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BridgeBio Oncology Therapeutics, Inc's Piotroski F-Score?
BridgeBio Oncology Therapeutics, Inc (BBOT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BridgeBio Oncology Therapeutics, Inc's earnings high quality?
BridgeBio Oncology Therapeutics, Inc (BBOT) has an earnings quality ratio of -0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.